Broxmeyer H E, Douglas G W, Hangoc G, Cooper S, Bard J, English D, Arny M, Thomas L, Boyse E A
Department of Medicine, (Hematology/Oncology), Indiana University School of Medicine, Indianapolis 46223.
Proc Natl Acad Sci U S A. 1989 May;86(10):3828-32. doi: 10.1073/pnas.86.10.3828.
The purpose of this study was to evaluate human umbilical cord blood as an alternative to bone marrow in the provision of transplantable stem/progenitor cells for hematopoietic reconstitution. Although no direct quantitative assay for human hematopoietic repopulating cells is at present available, the granulocyte-macrophage progenitor cell (CFU-GM) assay has been used with success as a valid indicator of engrafting capability. We examined greater than 100 collections of human umbilical cord blood for their content of nucleated cells and granulocyte-macrophage, erythroid (BFU-E), and multipotential (CFU-GEMM) progenitor cells, in many cases both before and after cryopreservation. First it was determined that granulocyte-macrophage, erythroid, and multipotential progenitor cells remained functionally viable in cord blood untreated except for addition of anticoagulant for at least 3 days at 4 degrees C or 25 degrees C (room temperature), though not at 37 degrees C, implying that these cells could be satisfactorily studied and used or cryopreserved for therapy after transport of cord blood by overnight air freight carriage from a remote obstetrical service. Granulocyte-macrophage progenitor cells from cord blood so received responded normally to stimulation by purified recombinant preparations of granulocyte-macrophage, granulocyte, and macrophage colony-stimulating factors and interleukin 3. The salient finding, based on analysis of 101 cord blood collections, is that the numbers of progenitor cells present in the low-density (less than 1.077 gm/ml) fraction after Ficoll/Hypaque separation typically fell within the range that has been reported for successful engraftment by bone marrow cells. Another observation of practical importance is that procedures to remove erythrocytes or granulocytes prior to freezing, and washing of thawed cells before plating, entailed large losses of progenitor cells, the yield of unwashed progenitor cells from unfractionated cord blood being many times greater. The provisional inference is that human umbilical cord blood from a single individual is typically a sufficient source of cells for autologous (syngeneic) and for major histocompatibility complex-matched allogeneic hematopoietic reconstitution.
本研究的目的是评估人类脐带血作为骨髓的替代物,用于提供可移植的干细胞/祖细胞以实现造血重建。尽管目前尚无针对人类造血重建细胞的直接定量检测方法,但粒细胞-巨噬细胞祖细胞(CFU-GM)检测已成功用作植入能力的有效指标。我们检查了100多份人类脐带血样本,检测其有核细胞、粒细胞-巨噬细胞、红系(BFU-E)和多能(CFU-GEMM)祖细胞的含量,许多样本在冷冻保存前后均进行了检测。首先确定,粒细胞-巨噬细胞、红系和多能祖细胞在未经处理的脐带血中保持功能活性,除添加抗凝剂外,在4℃或25℃(室温)下至少可存活3天,但在37℃下则不能,这意味着在通过隔夜航空运输从偏远产科服务机构运送脐带血后,这些细胞可以得到满意的研究、使用或冷冻保存用于治疗。如此获得的脐带血中的粒细胞-巨噬细胞祖细胞对粒细胞-巨噬细胞、粒细胞和巨噬细胞集落刺激因子以及白细胞介素3的纯化重组制剂的刺激反应正常。基于对101份脐带血样本的分析,最显著的发现是,在Ficoll/Hypaque分离后低密度(小于1.077 g/ml)部分中存在的祖细胞数量通常落在已报道的骨髓细胞成功植入的范围内。另一个具有实际重要性的观察结果是,在冷冻前去除红细胞或粒细胞的程序,以及在接种前对解冻细胞进行洗涤,会导致祖细胞大量损失,未分级脐带血中未洗涤的祖细胞产量要高很多倍。初步推断是,来自单个个体的人类脐带血通常是自体(同基因)和主要组织相容性复合体匹配的异基因造血重建的足够细胞来源。